Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Nutt

Showing results (701-710 of 790) with videos related to

Pageof 79
Sort By:
EJNMMI Research|August 1, 2018
First evaluation of PET-based human biodistribution and radiation dosimetry of <sup>11</sup>C-BU99008, a tracer for imaging the imidazoline<sub>2</sub> binding siteAshwin V Venkataraman, Nicholas Keat, James F Myers, et al.
Journal of Psychopharmacology (Oxford, England)|February 15, 2014
Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for PsychopharmacologyBlanca Bolea-Alamañac, David J Nutt, Marios Adamou, et al.
Addiction Biology|July 9, 2013
Investigating expectation and reward in human opioid addiction with [(11) C]raclopride PETBen J Watson, Lindsay G Taylor, Alastair G Reid, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|January 5, 2012
Characterisation of the contribution of the GABA-benzodiazepine α1 receptor subtype to [(11)C]Ro15-4513 PET imagesJames F M Myers, Lula Rosso, Ben J Watson, et al.
Journal of Psychopharmacology (Oxford, England)|November 8, 2005
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for PsychopharmacologyDavid S Baldwin, Ian M Anderson, David J Nutt, et al.
Journal of Psychopharmacology (Oxford, England)|November 14, 2022
Body mass index (BMI) does not predict responses to psilocybinMeg J Spriggs, Bruna Giribaldi, Taylor Lyons, et al.
Brain : a Journal of Neurology|September 13, 2023
A role for the serotonin 2A receptor in the expansion and functioning of human transmodal cortexAndrea I Luppi, Manesh Girn, Fernando E Rosas, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 11, 2018
Evaluation of <sup>11</sup>C-BU99008, a PET Ligand for the Imidazoline<sub>2</sub> Binding Site in Human BrainRobin J Tyacke, Jim F M Myers, Ashwin Venkataraman, et al.
Journal of Psychopharmacology (Oxford, England)|February 19, 2021
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorderBen Sessa, Laurie Higbed, Steve O'Brien, et al.
Scientific Reports|October 15, 2017
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanismsRobin L Carhart-Harris, Leor Roseman, Mark Bolstridge, et al.
Pageof 79

Showing results (701-710 of 790) with videos related to

Sort By:
Pageof 79
EJNMMI Research|August 1, 2018
First evaluation of PET-based human biodistribution and radiation dosimetry of <sup>11</sup>C-BU99008, a tracer for imaging the imidazoline<sub>2</sub> binding siteAshwin V Venkataraman, Nicholas Keat, James F Myers, et al.
Journal of Psychopharmacology (Oxford, England)|February 15, 2014
Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for PsychopharmacologyBlanca Bolea-Alamañac, David J Nutt, Marios Adamou, et al.
Addiction Biology|July 9, 2013
Investigating expectation and reward in human opioid addiction with [(11) C]raclopride PETBen J Watson, Lindsay G Taylor, Alastair G Reid, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|January 5, 2012
Characterisation of the contribution of the GABA-benzodiazepine α1 receptor subtype to [(11)C]Ro15-4513 PET imagesJames F M Myers, Lula Rosso, Ben J Watson, et al.
Journal of Psychopharmacology (Oxford, England)|November 8, 2005
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for PsychopharmacologyDavid S Baldwin, Ian M Anderson, David J Nutt, et al.
Journal of Psychopharmacology (Oxford, England)|November 14, 2022
Body mass index (BMI) does not predict responses to psilocybinMeg J Spriggs, Bruna Giribaldi, Taylor Lyons, et al.
Brain : a Journal of Neurology|September 13, 2023
A role for the serotonin 2A receptor in the expansion and functioning of human transmodal cortexAndrea I Luppi, Manesh Girn, Fernando E Rosas, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 11, 2018
Evaluation of <sup>11</sup>C-BU99008, a PET Ligand for the Imidazoline<sub>2</sub> Binding Site in Human BrainRobin J Tyacke, Jim F M Myers, Ashwin Venkataraman, et al.
Journal of Psychopharmacology (Oxford, England)|February 19, 2021
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorderBen Sessa, Laurie Higbed, Steve O'Brien, et al.
Scientific Reports|October 15, 2017
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanismsRobin L Carhart-Harris, Leor Roseman, Mark Bolstridge, et al.
Pageof 79